CYTH - Cyclo Therapeutics reports new positive data from early-stage rare genetic disorder study

Cyclo Therapeutics (NASDAQ:CYTH) announces new data from its Phase 1 extension study evaluating Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C1 (NPC), a rare, progressive and fatal genetic disorder characterized by abnormal accumulation of cholesterol in cells. The Company previously reported data on the Phase 1 extension study in January 2021 based on the initial efficacy results at a data cut-off of September 2020. The results summarized below have a data cut-off of July 2021. The safety profile of Trappsol Cyclo continues to be favorable, with no Adverse Events attributed to drug. Efficacy in 8 patients show a trend of stability for patients, with the mean length of exposure of 25 months. These findings provide additional support for the capacity of Trappsol Cyclo to stabilize disease progression in NPC1. The data are being presented at the National Niemann Pick Disease Foundation Family Support & Medical Conference being held July 29-August

For further details see:

Cyclo Therapeutics reports new positive data from early-stage rare genetic disorder study